Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...
Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...
Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...
Eli Lilly has partnered with Laekna to advance LAE102, an antibody targeting the ActRIIA receptor, for obesity and muscle ...
LAEKNA-B (02105.HK) announced a share placing immediately after a 48% share surge yesterday (20th). Today (21st), it opened ...
Laekna, Inc. (HK:2105) has released an update.Don't Miss out on Research Tools:Discover the latest stocks recommended by top Wall Street ...
LAEKNA-B (02105.HK) announced that it intends to place a total of 17.636 million shares pf the company, equivalent to about 4 ...
(Reuters) - Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle, the biotech said on ...
(Reuters) - Eli Lilly (LLY) and Hong Kong-listed Laekna (2105.HK) will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle ...
Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...